A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Influenza A virus H7N9 vaccines (Primary) ; AS03A
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 28 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 Planned initiation date changed from 3 Dec 2018 to 24 Dec 2018.